Latest Breaking News On - விரிவான இழப்பு - Page 7 : comparemela.com

Helix BioPharma Corp. Announces Fiscal Third Quarter 2021 Results OVERVIEW The Company reported a net loss and total comprehensive loss of $2,554,000 and $5,268,000 for the three and nine-month periods ended April 30, 2021. For the three and nine-month periods ended April 30, 2020, net loss and total comprehensive loss totalled $2,489,000 and $6,896,000, respectively. The net loss and total comprehensive loss for the three-month period ending April 30, 2021, includes a net loss of $nil (2020 - $198,000) and for the nine-month period ending April 30, 2021 a gain of $1,536,000 (2020 - loss of $465,000) from discontinued operations. The Company lost control of its subsidiary in Poland during the three-month period ending October 31, 2020 though continued to exert significant influence until December 22, 2020 when the Company disposed of its remaining interest for gross proceeds of $2,308,000.

Richmond hillFrank michalargiasPascal nigenHelix biopharma corpCompany interim condensed statement of financial positionCompany interim condensed financialFund managementMoffit cancer centreAlpha bronzeCompany interim condensed statement of net lossLind global macro fundHelix biopharmaInvestigational new drugMultijurisdictional disclosure systemAccounting oversight boardConsulting management